Status: Recruiting
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
Participants needed: 50
Trial details
Phase: Phase 2Age: 18-100Biological sex: FemaleType: InterventionalSponsor: Alessandro SantinUpdated: Jun 26, 2026Locations: 1
Eligibility criteria
Radiologically confirmed (ie, CT scan and/or MRI) persistent or recurrent endome... [+14]
Active or chronic corneal disorder [+12]